AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37120538 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study 37120538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37120593 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14) combined with azacitidine (75 mg/m2) and homoharringtonine
Number of subjects: 96
Study 37120593 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax combined with azacitidine and homoharringtonine
Number of subjects: 96
Study 37120600 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) - four cycles of 5-min pressure cuff inflation at 250 mmHg and deflation
Number of subjects: 50
Study 37120600 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 50
Study 37120671 — intervention group
Group type: EXPERIMENTAL
Intervention: SRA737 800 mg QD
Number of subjects: 107
Study 37120671 — intervention group
Group type: EXPERIMENTAL
Intervention: SRA737 1000 mg QD
Number of subjects: 107
Study 37120671 — intervention group
Group type: EXPERIMENTAL
Intervention: SRA737 1300 mg QD
Number of subjects: 107
Study 37120671 — intervention group
Group type: EXPERIMENTAL
Intervention: SRA737 monotherapy
Number of subjects: 107
Study 37120736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once-daily
Number of subjects: 112
Study 37120736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 37120774 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold EPM PRP
Number of subjects: 70
Study 37120774 — intervention group
Group type: COMPARATOR
Intervention: Threshold PRP
Number of subjects: 70
Study 37120800 — intervention group
Group type: EXPERIMENTAL
Intervention: PARENT intervention (community health worker as health educator); mean score for parent-reported receipt of recommended anticipatory guidance: 73.9 (SD, 23.4)
Number of subjects: 937
Study 37120800 — intervention group
Group type: COMPARATOR
Intervention: Usual care; proportion with ≥2 ED visits: 36.1%
Number of subjects: 937
Study 37120800 — intervention group
Group type: EXPERIMENTAL
Intervention: PARENT intervention; increased psychosocial assessments, greater number of developmental or behavioral concerns addressed, increased attendance at well-child visits, greater parental experiences with care
Number of subjects: 937
Study 37120902 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily enteral lipid supplementation with arachidonic acid (AA):docosahexaenoic acid (DHA) (100:50 mg/kg/day)
Number of subjects: 204
Study 37120902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion containing olive oil:soybean oil (4:1)
Number of subjects: 204
Study 37120902 — intervention group
Group type: EXPERIMENTAL
Intervention: Total phospholipid fatty acids
Number of subjects: 204
Study 37121237 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (100 mg tablet twice per day)
Number of subjects: 5438
Study 37121237 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg tablet once per day)
Number of subjects: 5438
Study 37121237 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 5438
Study 37121237 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5438
Study 37121237 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen and Aspirin
Number of subjects: 5438
Study 37121331 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided choledocho-duodenostomy (ECDS)
Number of subjects: 155
Study 37121331 — intervention group
Group type: COMPARATOR
Intervention: ERCP with covered metallic stents
Number of subjects: 155
Study 37121354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity transcranial ultrasound stimulation
Number of subjects: 0
Study 37121354 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 37121359 — intervention group
Group type: EXPERIMENTAL
Intervention: R-RALP with retroperitoneal CO2 insufflation
Number of subjects: 21
Study 37121391 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition (HD) videobronchoscopy
Number of subjects: 134
Study 37121390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking Matters for Diabetes (6-week diabetes and culinary education intervention)
Number of subjects: 0
Study 37121390 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Impact Ohio Central Ohio Pathways Hub intervention (community health worker model)
Number of subjects: 0
Study 37121390 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to the Mid-Ohio Farmacy (weekly access to fresh produce)
Number of subjects: 0
Study 37121390 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions combined
Number of subjects: 0
Study 37121533 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month PrI prevention intervention led by an occupational therapist
Number of subjects: 232
Study 37121533 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 232
Study 37121835 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with frankincense and myrrh essential oils
Number of subjects: 91
Study 37121835 — intervention group
Group type: COMPARATOR
Intervention: Massage with jojoba oil
Number of subjects: 91
Study 37121835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 91
Study 37121850 — intervention group
Group type: EXPERIMENTAL
Intervention: avelumab + best supportive care (BSC)
Number of subjects: 700
Study 37121850 — intervention group
Group type: COMPARATOR
Intervention: best supportive care (BSC)
Number of subjects: 700
Study 37121850 — intervention group
Group type: EXPERIMENTAL
Intervention: avelumab + BSC
Number of subjects: 700
Study 37121865 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 317
Study 37122050 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based HFNC (max flow of 2 L/kg per minute)
Number of subjects: 51
Study 37122050 — intervention group
Group type: COMPARATOR
Intervention: Standard HFNC (max flow of 8 L per minute)
Number of subjects: 51
Study 37122050 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based HFNC with protocolized weaning
Number of subjects: 51
Study 37122050 — intervention group
Group type: COMPARATOR
Intervention: Standard HFNC
Number of subjects: 51
Study 37122357 — intervention group
Group type: EXPERIMENTAL
Intervention: NUC and HBIG prophylaxis after OLT
Number of subjects: 31
Study 37122487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 8 weeks
Number of subjects: 214
Study 37122489 — intervention group
Group type: EXPERIMENTAL
Intervention: Falling Safely Training (FAST) program for 4 weeks
Number of subjects: 28
Study 37122489 — intervention group
Group type: COMPARATOR
Intervention: Evidence-based balance training (modified Otago exercise program)
Number of subjects: 28
Study 37122809 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 treatment in IFX-naïve patients
Number of subjects: 1233
Study 37122809 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 treatment in IFX ref patients
Number of subjects: 1233
Study 37122809 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 treatment in IFX bs patients
Number of subjects: 1233
Study 37123045 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 blockade
Number of subjects: 0
Study 37123046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 37123046 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 37124199 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based detection system for medication errors
Number of subjects: 0
Study 37124204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 0
Study 37124204 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37124504 — intervention group
Group type: EXPERIMENTAL
Intervention: Human intravital microscopy
Number of subjects: 0
Study 37124558 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid sinus node-sparing ablation procedure
Number of subjects: 142
Study 37124637 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 567
Study 37124637 — intervention group
Group type: COMPARATOR
Intervention: LDCT
Number of subjects: 567
Study 37124726 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE), 75 mg intramuscularly/month for 6 months
Number of subjects: 27
Study 37124726 — intervention group
Group type: COMPARATOR
Intervention: Testosterone undecanoate (TU), 250 mg intramuscularly every 3 months for 6 months
Number of subjects: 27
Study 37124732 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3-LCPUFAs (500-mg soft capsules, 0.100 g/kg of body weight/day for three months)
Number of subjects: 34
Study 37124732 — intervention group
Group type: EXPERIMENTAL
Intervention: ω3-LCPUFAs
Number of subjects: 34
Study 37124732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 34
Study 37124732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 37125046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate high fat diet (LCHF)
Number of subjects: 130
Study 37125046 — intervention group
Group type: COMPARATOR
Intervention: Vegan, vegetarian, and omnivorous diets
Number of subjects: 130
Study 37125397 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin D (5000 IU/day)
Number of subjects: 172
Study 37125397 — intervention group
Group type: COMPARATOR
Intervention: Low dose vitamin D (600 IU/day)
Number of subjects: 172
Study 37125459 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg tablets manufactured via twin-screw wet granulation (process 1)
Number of subjects: 0
Study 37125459 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat tablets manufactured via process 1 (1, 2, 4, 6, and 8 mg)
Number of subjects: 0
Study 37125459 — intervention group
Group type: COMPARATOR
Intervention: Daprodustat tablets manufactured via process 2 (1, 2, 4, 6, and 8 mg)
Number of subjects: 0
Study 37125484 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0
Study 37125484 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0
Study 37125484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37125490 — intervention group
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine
Number of subjects: 28
Study 37125490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 37125500 — intervention group
Group type: EXPERIMENTAL
Intervention: L-citrulline + Glutathione (Setria Performance Blend: SPB; L-citrulline [2 g] + glutathione [200 mg], 6 capsules)
Number of subjects: 25
Study 37125500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL; 3.1 g cellulose, 6 capsules)
Number of subjects: 25
Study 37125529 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg
Number of subjects: 1129
Study 37125529 — intervention group
Group type: COMPARATOR
Intervention: ramipril 5 mg
Number of subjects: 1129
Study 37125809 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled consent and expectation setting (experimental group)
Number of subjects: 261
Study 37125809 — intervention group
Group type: COMPARATOR
Intervention: Standard consent for invasive procedures (control group)
Number of subjects: 261
Study 37125811 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital tranexamic acid (TXA)
Number of subjects: 766
Study 37125811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study 37125831 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat, Sleep, Console approach
Number of subjects: 1305
Study 37125831 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Finnegan tool)
Number of subjects: 1305
Study 37125884 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation intervention consisting of weekly play sessions at home for 9 months, along with iron treatment for 6 months for IDA group.
Number of subjects: 372
Study 37125884 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention) for IDA children.
Number of subjects: 372
Study 37125891 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Early Childhood Development program delivered through community, group, and home-visiting platforms over 12-15 months.
Number of subjects: 1790
Study 37125891 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Early Childhood Development program
Number of subjects: 1790
Study 37125901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-resolution tomography Z-score neurofeedback (LZNFB)
Number of subjects: 87
Study 37125901 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta/beta neurofeedback (theta/beta NFB)
Number of subjects: 87
Study 37125901 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 87
Study 37125968 — intervention group
Group type: EXPERIMENTAL
Intervention: LAWT-guided pulmonary vein antrum isolation
Number of subjects: 121
Study 37126021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 10
Study 37126069 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/CT after intravenous administration of 296±20% MBq
Number of subjects: 0
Study 37126135 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the CHARM study
Number of subjects: 364
Study 37126208 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-loop contractility model using human cardiomyocytes
Number of subjects: 0
Study 37126326 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation
Number of subjects: 96
Study 37126326 — intervention group
Group type: EXPERIMENTAL
Intervention: Death
Number of subjects: 96
Study 37126326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors for transplant
Number of subjects: 96
Study 37126326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors for death
Number of subjects: 96
Study 37126332 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection (100 mL, intravenous infusion every 12 hours for 5 days)
Number of subjects: 1817
Study 37126332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (volume-matched saline, intravenous infusion every 12 hours for 5 days)
Number of subjects: 1817
Study 37126332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1817
Study 37126332 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 1817
Study 37126338 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal transitional care intervention including systematic medication reconciliation, a 15-minute patient education session with teach-back, a planned first follow-up visit with their primary care physician, and postdischarge follow-up telephone calls at 3 and 14 days.
Number of subjects: 1386
Study 37126338 — intervention group
Group type: COMPARATOR
Intervention: Usual care from hospitalist plus a 1-page standard study information sheet.
Number of subjects: 1386
Study 37126378 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth+I (n=74)
Number of subjects: 221
Study 37126378 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth (n=71)
Number of subjects: 221
Study 37126378 — intervention group
Group type: COMPARATOR
Intervention: Control (n=76)
Number of subjects: 221
Study 37126399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal testosterone gel 11 mg 3 times daily
Number of subjects: 81
Study 37126399 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular testosterone cypionate 200 mg every 2 weeks
Number of subjects: 81
Study 37126507 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-slip socks
Number of subjects: 0
Study 37126507 — intervention group
Group type: COMPARATOR
Intervention: Barefoot (Control)
Number of subjects: 0
Study 37126599 — intervention group
Group type: EXPERIMENTAL
Intervention: Minding the Baby® (MTB), an attachment-based home visiting intervention
Number of subjects: 97
Study 37126599 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 37126739 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (600 mg EPA and 300 mg DHA, twice daily)
Number of subjects: 40
Study 37126739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 37126770 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (regimen A, low-dose 20 mg/m2)
Number of subjects: 74
Study 37126770 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (regimen B)
Number of subjects: 74
Study 37126770 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (regimen A)
Number of subjects: 74
Study 37127045 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional dose (one-fifth of the standard dose) of 17D-213 yellow fever vaccine
Number of subjects: 250
Study 37127045 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of 17D-213 yellow fever vaccine
Number of subjects: 250
Study 37127047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional dose (one-fifth) of 17D-213 yellow fever vaccine
Number of subjects: 420
Study 37127047 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of 17D-213 yellow fever vaccine
Number of subjects: 420
Study 37127041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic decrease phase (June 1 to Dec 31, 2021)
Number of subjects: 22974
Study 37127041 — intervention group
Group type: COMPARATOR
Intervention: Pandemic escalation phase (March 1, 2020 to May 31, 2021)
Number of subjects: 22974
Study 37127211 — intervention group
Group type: EXPERIMENTAL
Intervention: Purse-string uterine suture
Number of subjects: 126
Study 37127211 — intervention group
Group type: COMPARATOR
Intervention: Double-layer continuous unlocked suture
Number of subjects: 126
Study 37127210 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene regimen (antibacterial mouth wash, dental floss, antibacterial toothpaste, power toothbrush, intensive oral hygiene education)
Number of subjects: 613
Study 37127210 — intervention group
Group type: COMPARATOR
Intervention: Usual oral hygiene care (standard oral home care instructions and regimen)
Number of subjects: 613
Study 37127210 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene regimen
Number of subjects: 613
Study 37127210 — intervention group
Group type: COMPARATOR
Intervention: Usual oral hygiene care
Number of subjects: 613
Study 37127210 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene regimen among unemployed participants with less favorable socioeconomic status
Number of subjects: 613
Study 37127210 — intervention group
Group type: COMPARATOR
Intervention: Usual oral hygiene care among unemployed participants with less favorable socioeconomic status
Number of subjects: 613
Study 37127523 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 77
Study 37127523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 37127526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabin strain inactivated poliovirus vaccine (sIPV)
Number of subjects: 500
Study 37127526 — intervention group
Group type: COMPARATOR
Intervention: Wild strain poliovirus vaccine (wIPV)
Number of subjects: 500
Study 37127558 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg for 4-8 weeks, then 10 mg for maintenance
Number of subjects: 208
Study 37127558 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole 30 mg for 4-8 weeks, then 15 mg for maintenance
Number of subjects: 208
Study 37127595 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth exercise intervention (30-60 min/session, 3 sessions/week)
Number of subjects: 20
Study 37127595 — intervention group
Group type: COMPARATOR
Intervention: Delayed control
Number of subjects: 20
Study 37127595 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth exercise intervention
Number of subjects: 20
Study 37127632 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMO2life® (1 g/l preservation solution)
Number of subjects: 0
Study 37127632 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (routine preservation solution)
Number of subjects: 0
Study 37127657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg naldemedine daily for 12 months
Number of subjects: 120
Study 37127657 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 12 months
Number of subjects: 120
Study 37127683 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of postoperative drains 3 hours after surgery in the absence of contraindications
Number of subjects: 72
Study 37127683 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest drain management
Number of subjects: 72
Study 37127754 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP/p300 HAT inhibitors
Number of subjects: 0
Study 37127754 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational KAT6A/B HAT inhibitor
Number of subjects: 0
Study 37127822 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=20)
Number of subjects: 82
Study 37127822 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (25% energy reduction; n=21)
Number of subjects: 82
Study 37127822 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction and exercise three times per week (n=20)
Number of subjects: 82
Study 37127822 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction and exercise six times per week (n=21)
Number of subjects: 82
Study 37128722 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported African American race
Number of subjects: 2427
Study 37128722 — intervention group
Group type: COMPARATOR
Intervention: Demographics, health status, and socioeconomic status adjustments
Number of subjects: 2427
Study 37128727 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (Group S)
Number of subjects: 40
Study 37128727 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 40
Study 37129110 — intervention group
Group type: EXPERIMENTAL
Intervention: Recast therapy embedded in a first-grade science curriculum
Number of subjects: 33
Study 37129110 — intervention group
Group type: COMPARATOR
Intervention: Active control (vocabulary + science)
Number of subjects: 33
Study 37129110 — intervention group
Group type: COMPARATOR
Intervention: Active control (phonological awareness + science)
Number of subjects: 33